Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Third-Quarter Earnings Portents

Executive Summary

Negative third-quarter earnings announcements from Vertex and Illumina are not good portents for an end of year life science rally and the absence of helpful positive announcements from Valeant and Gilead does not bode well either.

You may also be interested in...



Stockwatch: Earnings Season Inevitabilities

Johnson & Johnson, Actelion and Roche launched the 2016 third-quarter earnings season with a somewhat mixed opening salvo. The harsh investor response probably reflected an awareness of the inevitability of generic competition.

Stockwatch: Landscaping Earnings Announcements At Valeant And Endo

Endo, Valeant, Mylan and Perrigo all reported second-quarter results last week. Only maintenance of full-year guidance was needed for stock price outperformance but guidance cuts for all look like just a matter of time.

Stockwatch: Second-Quarter Earnings Highlight The Duracell Bunny PD-1 Inhibitor Race Winner

After the differing second-quarter financial performances of Roche, AstraZeneca and Pfizer’s oncology franchises, the reports by Merck & Co and BMS should have helped define the effects of the pandemic on oncology businesses.

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel